BioTuesdays

Category - Markets

Agrify
Markets

AGP starts Agrify at buy; PT $32

Alliance Global Partners initiated coverage of Agrify (NASDAQ:AGFY) with a “buy” rating and $32 price target. The stock closed at $16 on Oct. 29. “We see Agrify as an ancillary play on cannabis with the company’s...

November 1, 2021
AugMedix
Markets

WB starts Augmedix at OP

William Blair launched coverage of Augmedix (NASDAQ:AUGX) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. Augmedix provides a virtual medical documentation and live clinical support service, which...

November 1, 2021
Sigilon Therapeutics
Markets

BTIG starts Sigilon Therapeutics at buy; PT $14

BTIG launched coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a “buy” rating and price target of $14. The stock closed at $5.38 on Oct. 28. Sigilon is developing shielded living therapeutics (SLTs) as a “functional...

October 29, 2021
Protagenic Therapeutics
Markets

Maxim starts Protagenic Therapeutics at buy; PT $4

Maxim Group initiated coverage of Protagenic Therapeutics (NASDAQ:PTIX) with a “buy” rating and price target of $4. The stock closed at $1.80 on Oct. 28. Protagenic is developing its lead asset, PT00114, for the...

October 29, 2021
biophytis
Markets

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

October 25, 2021
Tempest Therapeutics
Markets

WB starts Tempest Therapeutics at OP

William Blair initiated coverage of Tempest Therapeutics (NASDAQ:TPST) with an “outperform” rating based on the potential of the company’s three first-in-class programs, including the dual EP2/EP4 antagonist, TPST-1495...

October 21, 2021
Jasper Therapeutics
Markets

WB starts Jasper Therapeutics at OP

William Blair launched coverage of Jasper Therapeutics (NASDAQ:JSPR) with an “outperform” rating based on the potential for JSP191 to transform the bone marrow transplant field through safer and more-effective...

October 21, 2021
Atea Pharmaceuticals
Markets

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

October 20, 2021
Vicarious-Surgical
Markets

BTIG starts Vicarious Surgical at buy; PT $15

BTIG initiated coverage of Vicarious Surgical (NYSE:RBOT) with a “buy” rating and $15 price target. The stock closed at $10.57 on Oct.15. Vicarious Surgical is a pre-commercial development-stage surgical robotics...

October 18, 2021